AAAAAA

   
Results: 1-9 |
Results: 9
Issues in antithrombin therapy for UA/NSTEMI
Authors: Alpert, JS Budaj, AJ Gurfinkel, EP Henry, TD
Citation: Js. Alpert et al., Issues in antithrombin therapy for UA/NSTEMI, EUR H J SUP, 3(J), 2001, pp. J15-J23
Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease
Authors: Henry, TD Rocha-Singh, K Isner, JM Kereiakes, DJ Giordano, FJ Simons, M Losordo, DW Hendel, RC Bonow, RO Eppler, SM Zioncheck, TF Holmgren, EB McCluskey, ER
Citation: Td. Henry et al., Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease, AM HEART J, 142(5), 2001, pp. 872-880
Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Authors: Henry, TD Satran, D Knox, LL Iacarella, CL Laxson, DD Antman, EM
Citation: Td. Henry et al., Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?, AM HEART J, 142(4), 2001, pp. 590-593
Monitoring plasma cardiac troponin I for the detection of myocardial injury after percutaneous transluminal coronary angioplasty
Authors: Ricchiuti, V Shear, WS Henry, TD Paulsen, PR Miller, EA Apple, FS
Citation: V. Ricchiuti et al., Monitoring plasma cardiac troponin I for the detection of myocardial injury after percutaneous transluminal coronary angioplasty, CLIN CHIM A, 302(1-2), 2000, pp. 161-170
sFlt-1, a potential antagonist for exogenous VEGF - Response
Authors: Henry, TD Annex, BH Zioncheck, TF
Citation: Td. Henry et al., sFlt-1, a potential antagonist for exogenous VEGF - Response, CIRCULATION, 102(15), 2000, pp. E108-E109
Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion - Evidence for a dose-dependent effect
Authors: Hendel, RC Henry, TD Rocha-Singh, K Isner, JM Kereiakes, DJ Giordano, FJ Simons, M Bonow, RO
Citation: Rc. Hendel et al., Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion - Evidence for a dose-dependent effect, CIRCULATION, 101(2), 2000, pp. 118-121
First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of theTIMI 15A and 15B trials
Authors: Giugliano, RP McCabe, CH Sequeira, RF Frey, MJ Henry, TD Piana, RN Tamby, JF Jensen, BK Nicolas, SB Jennings, LK Wise, RJ Braunwald, E
Citation: Rp. Giugliano et al., First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of theTIMI 15A and 15B trials, AM HEART J, 140(1), 2000, pp. 81
Preclinical evaluation of a Rheolytic (TM) catheter for percutaneous coronary artery/saphenous vein graft thrombectomy
Authors: Henry, TD Setum, CM Wilson, GJ Morris, JE Johnston, RB Jenson, ML
Citation: Td. Henry et al., Preclinical evaluation of a Rheolytic (TM) catheter for percutaneous coronary artery/saphenous vein graft thrombectomy, J INVAS CAR, 11(8), 1999, pp. 475-484
Science, medicine, and the future - Therapeutic angiogenesis
Authors: Henry, TD
Citation: Td. Henry, Science, medicine, and the future - Therapeutic angiogenesis, BR MED J, 318(7197), 1999, pp. 1536-1539
Risultati: 1-9 |